Evidence based guidelines for the treatment of primary headaches;Smjernice za liječenje primarnih glavobolja zasnovane na dokazima

Acta Medica Croatica

Volumn 62, Issue 2, 2008, Pages 99-136

  Demarin, Vida ^a   Vuković, Vlasta ^a   Lovrenčić Huzjan, Arijana ^a   Lušić, Ivo ^b   Jančuljak, Davor ^c   Wilheim, Katja ^d   Zurak, Nko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^d KBC RIJEKA   (Croatia)

Author keywords

Cluster headache; Headache treatment; Migraine; Pharmacotherapy; Tension headache

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; CAFFEINE; CHLORPROMAZINE; CODEINE; DEXAMETHASONE; DICLOFENAC; DIHYDROERGOTAMINE; ELETRIPTAN; FROVATRIPTAN; GRANISETRON; HYDROCORTISONE; IBUPROFEN; KETOROLAC; LIDOCAINE; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PARACETAMOL; PIROXICAM; PROCHLORPERAZINE; RIZATRIPTAN; SUMATRIPTAN; THIETHYLPERAZINE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

ACUPUNCTURE; AKATHISIA; ALTERNATIVE MEDICINE; BEHAVIOR THERAPY; CLUSTER HEADACHE; CROATIA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; DUODENUM BLEEDING; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FEEDBACK SYSTEM; HEADACHE; HUMAN; HYPNOSIS; MANIPULATIVE MEDICINE; MIGRAINE; MIGRAINE WITH AURA; MONOTHERAPY; NEUROLOGIC EXAMINATION; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PRIMARY HEADACHE; RETINAL MIGRAINE; REVIEW; REYE SYNDROME; SEDATION; SIDE EFFECT; STOMACH HEMORRHAGE; SYMPTOMATOLOGY; TENSION HEADACHE; TRANSCUTANEOUS NERVE STIMULATION; TRANSFORMED MIGRAINE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EVIDENCE-BASED MEDICINE; HEADACHE DISORDERS, PRIMARY; HUMANS;

EID: 48349093145     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (235)

1. Goadsby P, Olesen J. Diagnosis and management of migraine. BMJ 1996; 312: 1279-83.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004; 24(suppl 1): 14-15.
3. American College of Emergency Physicians (ACEP). Clinical policy: critical isssues in the evaluation and management of patients presenting to the emergency department with acute headache. Ann Emerg Med 2002; 39: 108-22.
4. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. U: Silberstein SD, Lipton RB, Dalessio DJ, ur. Wolf's headache and other head pain, 7th ed. Oxford: Oxford University Press 2001, 121-237.
5. Frishberg BM, Rosenberg JH, Matchar DB i sur. Evidence-Based Guidelines in the primary Care Setting: Neuroimaging in Patients with Nonacute Headache. Available at http://www.aan.com. Accessed May 2003.
6. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42: 501-509.
7. Rasmussen BK, Jensen R, Schroll M i sur. Epidemiology of headache in general population: a prevalence study. J Clin Epidemiol 1991; 44: 1147-57.
8. Stewart WF, Lipton RB, Celentano DD i sur. Prevalence of migraine headache in the United States. JAMA 1992; 267: 64-9.
9. O'Brien B, Goeree R, Steiner D. Prevalence of migraine headache in Canada: a population-based survey. J Epidemiol 1994; 23: 1020-26.
10. Henry P, Michel P, Brochet B i sur. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992; 12: 229-37.
11. Stewart WF, Lipton RB, Liberman J. Variations in migraine prevalence by race. Neurology 1996; 47: 52-9.
12. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43(suppl 3): 16-20.
13. Demarin V, Rundek T, Podobnik Šarkanji S, Lovrenčić Huzjan A. A correlation of 5-hydroxytriptarnine and cerebral vasoreactivity in patients with migraine. Funct Neurol 1994; 9: 235-45.
14. Lovrenčić Huzjan A, Demarin V, Rundek T, Šerić V. Cerebral haemodynamic changes during migraine attack Period Biol 1995; 97: 127-32.
15. Lovrenačić Huzjan A, Demarin V, Rundek T, Vuković V. Role of vertebral artery hypoplasia in migraine. Cephalalgia 1998; 18: 684-6
16. Lovrenačić Huzjan A, Demarin V, Malić M. Sumatriptan ne uzrokuje značajnu moždanu vazokonstrikciju u migreni. Neurol Croat 1999; 48: 119-26.
17. Lovrenačić Huzjan A, Demarin V. Cerebral hemodynamic changes in migraine patients overusing ergotamine: four case reports. Acta Clin Croat 1999; 38: 245-50.
18. Peroutka SJ. Genetic basis of migraine. Clin Neurosd 1998; 5: 34-7.
19. Ducros A, Tournier-Lasserve E, Bousser MG. The genetics of migraine. Lancet Neurol 2002; 5: 285-93.
20. American Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994; 44: 1353-54.
21. Evans R, Rozen TD, Adelman JU. Neuroimaging and other diagnostic testing in headache. U: Silberstein SD, Lipton RB, Dalessio DJ, ur. Wolf's headache and other head pain, 7th ed. Oxford: Oxford University Press, 2001, 27-49.
22. Živadinov R, Wilheim K, Sepić-Grahovac D i sur. Migraine and tension-type headache in Croatia: a population-based survey of predpitating factors. Cephalalgia 2003; 23: 336-43.
23. Blau JN. Adult migraine: the patient observed. U: Blau JN, ur. Migraine: clinical, therapeutic, conceptual and research aspects. London: Chapman and Hall, 1987, 3-30.
24. Peatfield RC. Relationships between food, wine and, beer precipitated migranious headaches. Headache 1995; 35: 355-7.
25. Forward SP, McGrath PJ, MacKinnon D i sur. Medication patterns of recurrent headache sufferers: a community study. Cephalalgia 1998; 18: 146-51.
26. Matchar DB, Young WB, Rosenberg JH i sur. Evidence-Based Guidelines in the primary Care Setting: Pharmacological Management of Acute Attacks. Available at: http://www.aan.com. Accessed May 2003.
27. Silberstein SD. Practice parameter-evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 2000; 55: 754-62.
28. Snow V, Weiss K, Wall E, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137: 840-52.
29. Lovrenačić Huzjan A, Herceg M, Bilušić M, Ivančan V. Lijekovi s ucǐnkom na živčani sustav. U: Vrhovac B, ur. Farmakoterapijski priručnik, 4. izd. Zagreb: Medicinska naklada, 2003, 437-526.
30. Tfelt-Hansen P, Henry P, Mulder Lj i sur. The effectiveness of combined oral lysine acetylsalydlate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-6.
31. Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology and efficacy. Headache 2001; 41: 953-67.
32. Silberstein SD, McCrory DS. Opioids. Cephalalgia 2000; 20: 854-64.
33. Klapper J, Stanton J. The emergency treatment of acute migraine headache: a comparison of intraveneous dihydroergotamine, dexamethasone and placebo. Cephalalgia 1991; 11(suppl 11): 159-60.
34. Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double blind, controlled trial. JAMA 1996; 276: 319-21.
35. Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intraveneous prochlorperazine for the treatment of acute headache. JAMA 1989; 264: 261-76.
36. Carpay JA, Linssen HJP, Koehler JJ, Arends LR, Tiedink HGM. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. Headache 2003; 43: 395-99.
37. Ferrari MD. The subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New Engl J Med 1991; 325: 316-21.
38. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-8.
39. Tfelt-Hansen P. A comparative review of pharmacology, pharmacokinetics and efficacfy of triptans in migraine. Drugs 2000; 6: 1259-37.
40. Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468-78.
41. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel group study. Headache 1997; 37: 640-5.
42. Block GA, Goldstein J, Polis A, Reines SA, Smith ME. The Rizatriptan Multicenter Study Group. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998; 38: 764-71.
43. Kramer MS, Matzura-Wolfe D, Polis A i sur. A placebo-controlled cross-over study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-81.
44. Mathew NT. Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12. 5 mg for the treatment of acute migraine. Headache 2002; 42: 32-40.
45. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine; defining the optimum doses for oral sumatriptan. Headache 1998; 38: 184-90.
46. Dahlof C, Fabri M, Loftus J, Jones M, Mansbach H, Scott A. Triptan efficacy and preference: results of a randomized, multi-centre, open-label, crossover study of sumatriptan, naratriptan, rizatriptan and zolmitriptan tablets in acute treatment of migraine. Cephalalgia 2001; 21: 410.
47. Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000; 7(suppl 3): 82.
48. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997; 17: 421.
49. Buchan P, Ward C, Zeig S. Frovatripan pharmacokinetics are unaffected during a migraine attack. Cephalalgia 1999; 19: 365.
50. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241: 138-44.
51. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995; 45(suppl 7): 10-14.
52. Rederich G, Rapoport A. Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995; 45 (suppl 7): 15-20.
53. Dahlof C, Diener HC, Goadsby PJ i sur. Zolmitriptan, a 5-HT 1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998; 5: 535-43.
54. Steiner TJ. Eletriptan Steering Committee. Eficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine: results of a phase III study. Cephalalgia 1998; 18: 385.
55. Goadsby PJ, Ferrari MD, Olesen J i sur. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156-63.
56. Robert M, Cabarrocas X, Fernandez FJ, Zayas JM, Ferrer P. Almotriptan Multiple Attack Study Group. Efficacy and tolerability of oral almotriptan in the treatment of migraine. Cephalalgia 1998; 18: 406.
57. McDavis HL, Hutchinson J. Frovatriptan phase III Investigators. Frovatriptan - new overall clinical efficacy. Cephalalgia 1999; 19: 363-4.
58. Mauskop A, Farkkila M, Hering-Hanit R, Rapoport A, Warner J. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Curr Med Res Opin 1999; 15: 282-9.
59. Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999; 12: 403-17.
60. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of meta-analysis of 53 trials. Cephalalgia 2002; 22; 633-58.
61. Lipton RB, Cady RK, O Quinn S, Hall CB, Stewart WF. Sumatriptan treats the full spectrum of headache in individuals with disabling HIS migraine. Headache 1999; 40: 783-91.
62. Hall GC, Brown MM, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-8.
63. Goldstein JA, Massey KD, Kirby S i sur. Effect of high-dose intraveneous eletriptan on coronary artery diameter. Cephalalgia 2004; 24: 515-21.
64. Ferrari MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 19(suppl 23): 2-8.
65. Silberstein SD. Migraine. Lancet 2004; 363: 381-91.
66. Geraud, G, Keywood C, Senarsd JM. Migraine headache recurrence to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003; 43: 376-88.
67. Lofland JH, Kim SS, Batenhorst AS i sur. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001; 76: 1093-101.
68. Tfelt-Hansen P, Saxena PR, Dahlof C i sur. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123: 9-18.
69. Mathew NT. Dosing and administration of ergotamine tartarate and dihydroergotamine. Headache 1997; 37(suppl 1): 26-32.
70. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361-5.
71. Evers S, Gralow I, Bauer B i sur. Sumatriptan and ergotamine overuse and drug induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22: 201-6.
72. Lipton RB. Ergotamine tartarate and dihydroergotamine mesylate: safety profiles. Headache 1997; 37(suppl 1): 33-41.
73. Ad hoc committee for the diagnostic and therapeutic guidelines for migraine and cluster headache. Prophylactic treatment of migraine. J Headache Pain 2001; 2: 147-61.
74. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.
75. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-Based Guidelines in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. Available at: http://www.aan.com. Accessed May 2003.
76. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998; 56: 811-24.
77. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoreceptor blockers. Br J Clin Pharmacol 2001; 52: 237-43.
78. Anderson K, Vinge E. Beta-adrenoreceptor blockers and caldum antagonists in the prophylaxis and treatment of migraine. Drugs 1990; 39: 355-73.
79. Holroyd KA, Penzien DB, Coordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991: 31: 333-40.
80. Olesen J, Tfelt-Hansen P, Welch KMA, ur. The headaches. New York: Raven press, 1993.
81. Kangasniemi P, Andersen AR, Andersen PG i sur. Classic migraine effective prophylaxis with metoprolol. Cephalalgia 1987; 7: 231-8.
82. Frishman WH. Beta adrenergic blocker withdrawal. Am J Cardiol 1987; 59: 32 F.
83. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695-9.
84. Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. Trans Am Neurol Assoc 1976; 101: 234-7.
85. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache 1981; 21: 105-9.
86. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34: 476-78.
87. Oguzhanoglu A, Sahiner T, Kurt T, Akalin O. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension type headache. Cephalalgia 1999; 19: 531-32.
88. Diener HC, Föh M, Iaccarino C i sur. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996; 16: 441-7.
89. Diamond S, Freitag FG. A double blind trial of flunarizine in migraine prophylaxis. Headache 1993; 4: 169-72.
90. Louis P. A double-blind placebo controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981; 21: 235-9.
91. Mendenopoulos G, Manafi T, Logothetis I, Bostantjopoilou S. Flunarizine in the prevention of dassical migraine: a placebo-controlled evaluation. Cephalalgia 1985; 5: 31-7.
92. Gawel MJ, Kreeft J, Nelson RF i sur. Comparison of the efficacy and safety of funarizine ot propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992; 19: 340-5.
93. Sorensen PS, Laresn BH, Rasmussen MJ i sur. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 10: 657.
94. Cleland PG, Barnes D, Elrington GM i sur. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997; 38: 31-8.
95. Silberstein SD. Methysergide. Cephalalgia 1998; 18: 421-35.
96. Peatifield R. Drugs acting by modification of serotonin function. Headache 1986; 26: 129-31.
97. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986; 26: 83-5.
98. Forssman B, Henriksson KG, Kihlstrand S. A comparison between BC105 and methysergide in the prophylaxis of migraine. Acta Neurol Scand 1972; 48: 204-12.
99. Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 1985; 5: 17-23.
100. Behan PO, Reid M. Propranolol in the treatment of migraine. Practitioner 1980; 224: 201-4.
101. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12: 81-4.
102. Klapper JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Q 1995; 5: 50-3.
103. Klapper JA. Divalproex sodium in migraine prophylaxis: a dose controlled study. Cephalalgia 1997; 17: 103-8.
104. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994; 44: 647-51.
105. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54: 1141-5.
106. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group). Headache 1999; 39: 633-43.
107. Mathew NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996; 16: 367.
108. Mathew NT, Rapoport A, Saper J i sur. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-28.
109. Wessely P, Baumgartner C, Winger D i sur. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia 1987; 7: 477-8.
110. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 2000; 54: A15(abstract)
111. Edwards KR, Glantz MJ, Shea P, Norton JA, Cross N. A double blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. Cephalalgia 2000; 20: 316(abstract).
112. Sterner TJ, Findley Lj, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-112.
113. D' Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectivenesss of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 9: 64-66.
114. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura-a pilot study. Cephalalgia 1999; 19: 58-63.
115. O'Neal BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1978; 2: 1179-81.
116. Masel BE, Chesson AL, Peters BH, Levin HS, Alperin JB. Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. Headache 1980; 20: 13-18.
117. Salomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. Cleve Clin J Med 1993; 60: 43-48.
118. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen in migraine prophylaxis. Headache 1974; 14: 96-100.
119. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetii F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30: 705-9.
120. Szekel B, Merryman S, Croft H, Post G. Prophylactic effect of naproxen sodium on perimenstrual headache: a double blind placebo controlled study. Cephalalgia 1989; 9 (suppl 10): 452-3.
121. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470.
122. Volger BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18: 704-8.
123. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523-32.
124. Boska MD, Welch KMA, Barker PB, Nelson JA, Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002; 58: 1227-33.
125. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective multi-center, placebo-controlled and double blind randomized study. Cephalalgia 1996; 16: 257-63.
126. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels. (Abstract). Neurology 1995; 45: A379.
127. Montagna P, Cortelli P, Barbiroli B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia 1994; 14: 184-93.
128. Bresolin N, Martinelli P, Barbiroli B i sur. Musde mitochondrial deletion and 31P NMR spectroscopy alterations in migraine patients. J Neurol Sci 1991; 104: 182-9.
129. Barbiroli B, Montagna P, Martinelli P i sur. Improved brain and musde energy metabolism in patients with mitochondrial cytopathies treated with coenzyme Q10. Neurol 1994; 2 (suppl): 404.
130. Rozen TD, Oshinsky ML, Gebeline CA i sur. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 37-41.
131. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445-50.
132. Brin MF, Swope DM, O Brian C, Abbasi S, Pogoda JM. Botox for migraine: double-blind, placebo-controlled, region specific evaluation. Cephalalgia 2000; 20: 421-2.
133. Binder WJ. Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123: 669-76.
134. Mauskop A, Basdeo R. Botulinum toxin is an effective prophylactic therapy for migraines. Cephalalgia 2000; 20: 422.
135. Evers S, Rahmann J, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A - a review according to evidence - based medicine criteria. Cephalalgia 2002; 22: 699-710.
136. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251 (suppl 1): 8-11.
137. Eftedal OS, Lydersen S, Heide G, White L, Brubakk AO, Stovner Lj. A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine. Cephalalgia 2004; 24: 639-44.
138. Myers DE, Myers RA. A preliminary report on hyperbaric oxygen in the relief of migraine headache. Headache 1995; 35: 197-9.
139. Wilson JR, Foresman BH, Ga, ber RG, Wright T. Hyperbaric oxygen in the treatment of migraine with aura. Headache 1998; 38: 112-5.
140. Soyka D, Frieling B. Lisuride for the prevention of migraine. Results of a multicenter study. Fortschr Med 1989; 107: 763-6.
141. Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache 2003; 43: 482-9.
142. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refradory migraine and chronic daily headache. Headache 2002; 42: 515-8.
143. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology 2003; 60: 1064-70.
144. Ad hoc committee for the diagnostic and therapeutic guidelines for migraine and cluster headache. Prophylactic treatment of migraine. J Headache Pain 2001; 2: 62-7.
145. Daly EJ, Donn PA, Galliher MJ, Zimmerman JS. Biofeedback applications to migraine and tension headaches: a double-blinded outcome study. Biofeedback Self Regul 1983; 8: 135-52.
146. Brown JM. Imagery coping strategies in the treatment of migraine. Pain 1984; 18: 157-67.
147. Sorbi M, Tellegen B. Differential effects of training in relaxation and stress-coping in patients with migraine. Headache 1986; 26: 473-81.
148. Sargent J, Solbach P, Coybe L, Psohn H, Segerson J. Results of a controlled, experimental, outcome study of non drug treatment for the control of migraine headaches. J Behav Med 1986; 9: 291-323.
149. Bild R, Adams HE. Modification of migraine headaches by cephalic blood volume pulse and EMG biofeedback. J Consult Clin Psychol 1980; 48: 51-7.
150. Gauthier J, Lacroix R, Cote A, Doyon J, Drolet M. Biofeedback control of migraine headaches: a comparison of two approaches. Biofeedback Self Regul 1985; 10: 139-59.
151. Blanchard EB, Appelbaum KA, Radnitz CL i sur. A controlled evaluation of thermal biofeedback combined with cognitive therapy in the treatment of vascular headache. J Consult Clin Psychol 1990; 58: 216-24.
152. Blanchard EB, Appelbaum KA, Nicholson NL i sur. A controlled evaluation of the addition of cognitive therapy to a home-based biofeedback and relaxation treatment of vascular headache. Headache 1990; 30: 371-76.
153. Marcus DA, Scharff L, Mercer S, Turk DC. Non-pharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback. Cephalalgia 1998; 18: 266-72.
154. Holroyd KA, France JL, Cordingley GE i sur. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. J Consult Clin Psychol 1995; 63: 327-30.
155. Kisch I. Hypnosis as an adjunct to cognitive-behavioral psychotherapy: a meta-analysis. J Consult Clin Psychol 1995; 63: 214-20.
156. Ad hoc committee for the diagnostic and therapeutic guidelines for migraine and cluster headache. Non-pharmacological therapy of migraine. J Headache Pain 2001; 2: 162-7.
157. Parker GB, Tupling H, Pryor DS. A controlled trial of cervical manipulation of migraine. Aust N Z J 1978; 8: 589-93.
158. Nelson CF, Bronfort G, Evans R. Boline P, Goldsmith C, Anderson R. The efficacy of spinal manipulation, amytriptiline and the combination of both therapies for the prophylaxis of migraine headache. J Manipulative Physiol Ther 1998; 21: 511-19.
159. MacGregor EA. »Menstrual« migraine: towards a definition. Cephalalgia 1996; 16: 11-21.
160. Bousser MG, Conrad J, Kittner S i sur. Recommendations on the risk of ichaemic stroke assodated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia 2000; 20: 155-6.
161. Massiou H, MacGregor FA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000; 20: 170-4.
162. Dennerstein L, Morse C, Burrows G i sur. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2: 113-20.
163. Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia 1993; 13(suppl 13): 244.
164. Institute for Clinical Systems Improvement (ICSI). Migraine headache. Available at: http://www.neurology.org. Accessed May 2003.
165. Becker J. Use of oral contraceptives in patients with migraine. Neurology 1999; 53 (suppl. 1): 19-25.
166. Silberstein SD, DeLignieres B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000; 20: 214-21.
167. Silberstein SD. Headache and female hormones: what you need to know. Neurology 2001; 14: 323-33.
168. Etminam M, Takkouche B, Caamano I, Samii A. Risk of ischemic stroke in people with migraine: systematic review and meta-analysis of observational studies. Available at: http://www.bmj.com. Accessed December 2004.
169. Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic stroke and active migraine. Neurology 2001; 27: 1805-11.
170. Vuković V, Lovrenačić Huzjan A, Vargek Solter V, Crossed D signorCrossed d signević V, Demarin V. Hormone replacement therapy-is there a place for its use in neurology? Coll Antropol 2003; 27: 413-24.
171. Sances G, Granella F, Nappi RE i sur. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23: 197-205.
172. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of The International Headache Sodety. Cephalalgia 1991; 11: 129-34.
173. Goadsby PJ, Boes C. Chronic daily headache. J Neurol Neurosurg Psychiatry 2002; 72 (suppl 2): 2-5.
174. Ashina M, Bendtsen L, Jensen R, Sakai F, Olesen J. Musde hardness in patients with chronic tension-type headache: relation to actual headache state. Pain 1999; 79: 201-5.
175. Jensen R, Bendsen L, Olesen J. Muscular fadors are of importance in tension-type headache. Headache 1998; 38: 10-17.
176. Bendsen L. Central senzitization in tension-type headache-possible pathophysiological mechanisms. Cephalalgia 2000; 20: 486-508.
177. Jensen R, Olesen J. Tension-type headache: an update on mechanisms and treatment. Curr Opin Neurol 2000; 13: 285-9.
178. Holroyd KA, O'Donell FJ, Stensland M i sur. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination. A randomized controlled trial. J Am Med Assoc 2001; 285: 2208-15.
179. Cerbo R, Barbanti P, Fabbrini G i sur. Amitriptyline is effective in chronic but not in episodic tensiontype headache: pathogenic implications. Headache 1998; 38: 453-7.
180. Bussone G, Sandrini G, Patruno G i sur. Effectiveness of fluoxetine on pain and depression in chronic headache disorders. U: Nappi G, Bobo G, Sandrini G, ur. Headache and depression: serotonin pathways as a common due. New York: Raven Press, 1991, 265-72.
181. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004; 24: 60-5.
182. Relja M, Telarović S. Botulinum toxin in tension-type headache. J Neurol 2004; 251 (suppl 1): 12-14.
183. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin. A pilot study. Eur J Med Res 1999; 4: 183-6.
184. Relja M. Treatment of tension-type headache with botulinum toxin: 1 year-follow-up. Cephalalgia 2000; 20: 236.
185. Padberg M, de Bruijn SFTM, de Haan RJ, Tavy DLj. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004; 24: 675-80.
186. Manzoni GC, Mideli G, Granella F, Tassorelli C, Zanferrari C, Cavallini A. A cluster headache-course over ten years in 189 patienrs. Cephalalgia 1991; 11: 169-74.
187. Ekbom K. Pattern of cluster headache with a note on the relation to angina pectoris and peptic ulcer. Acta Neurol Scand 1970; 46: 225-37.
188. Manzoni GC. Epidemiological and clinical aspects of cluster headache: relation with the migrainous syndrome. Ital J Neurol Sci 1999; 20: 6-7.
189. Manzoni GC, Terzano MG, Bono G, Mideli G, Martucri N, Nappi G. Cluster headache-clinical findings in 180 patients. Cephalalgia 1983; 3: 21-30.
190. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA 1962; 179: 717-18.
191. Haimanot RT, Seraw B, Forsgren L, Ekbom K, Ekstedt J. Migraine, chronic tension-type headache and cluster headache in an Ethiopian rural community. Cephalalgia 1995; 15: 482-8.
192. Russell MB, Andersson PG, Thomsen LL. Familial occurrence of cluster headache. J Neurol Neurosurg Psychiatry 1995; 58: 341-3.
193. Italian Cooperative Study Group on the Epidemiology of Cluster Headache (ICECH). Case-control study on the epidemiology of cluster headache I: Etiological factors and associatiated conditions. Neuroepidemiology 1995; 14: 123-7.
194. Ad hoc committee for the diagnostic and therapeutic guidelines for migraine and headache. Diagnosis, symptomatic therapy and preventive therapy of cluster headache. J Headache Pain 2001; 2: 168-79.
195. Demarin V i sur. Priručnik iz neurologije. Zagreb: Prosvjeta, 1998.
196. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991; 325: 322-6.
197. Ekbom K, Monstad I, Prusinski A, Cole JA, Pilgrim AJ, Noronha D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Stiudy Group. Acta Neurol Scand 1993; 88: 63-9.
198. Ekbom K, Krabbe E, Mideli G i sur. Cluster headache attacks treated for up to three month with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-Term Study Group. Cephalalgia 1995; 15: 230-6.
199. Göbel H, Lindner V, Heinze A, Ribbat M, Deuschl G. Acute therapy for cluster headache with sumatriptan: findings of one-year long-term study. Neurology 1998; 51: 908-11.
200. Hardebo JE. Subcutaneous sumatriptan in cluster headache: a time study of the effect on pain and autonomic symptoms. Headache 1993; 33: 18-21.
201. Hardebo JE, Dahlöf C. Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache. Cephalalgia 1998; 18: 487-9.
202. Bahra A, Gawel MJ, Hardebo JE, Millson D, Breen SA, Goadsby PJ. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000; 54: 1832-9.
203. Fogan L. Treatment of cluster headache. A double blind comparison of oxygen vs. air inhalation. Arch Neurol 1985; 42: 362-3.
204. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981; 21: 1-4.
205. Di Sabato F, Fusco BM, Pelaia P, Giacovazzo M. Hyperbaric oxygen therapy in cluster headache. Pain 1993; 52: 243-5.
206. Porta M, Granella F, Coppola A, Longoni C, Manzoni GC. Treatment of cluster headache attacks with hyperbaric oxygen. Cephalalgia 1991; 11(supl 11): 236-7.
207. Horton BT, Ryan R, Reynolds JL. Clinical observations on the use or E. C. 110, a new agent for the treatment of headache. Proc Mayo Clin 1948; 23: 105-8.
208. Magee KR, Westerberg MR, DeJong RM. Treatment of headache with ergotamine caffeine suppositories. Neurology 1952; 2: 477-30.
209. Anderson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986; 6: 51-4.
210. Robbins L. Intranasal lidocaine for cluster headache. Headache 1995; 35: 83-4.
211. Gabai IJ, Spielings EL. Prophylactic treatment of cluster headache with verapamil. Headache 1989; 29: 167-8.
212. Leone M, D'Amico D, Ferdiani F i sur. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus palcebo. Neurology 2000; 54: 1382-5.
213. Prusinsky A, Kozubsky W, Szulc-Kuberska J. Steroid treatment in the interruptions of clusters in cluster headache patients. Cephalalgia 1987; (suppl 6): 332-3.
214. Anthony M, Daher BM. Mechanism of action of steroids in cluster headache. U: Rose FC, ur. New advances in headache research. London: Smith-Gordon, 1992, 271-4.
215. Ekbom K, Olivarius B. Chronic migrainous neuralgia: diagnostic and therapeutic aspects. Headache 1971; 11: 97-101.
216. Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981; 21: 132-9.
217. Bussone G, Leone M, Peccarisi C i sur. Doubleblind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990; 30: 411-7.
218. Steiner TJ, Hering R, Couturier EG, Davies PT, Whitmarsh TE. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997; 17: 673-5.
219. Ekbom K. Prophylactic treatment of cluster headache with a new serotonin antagonist, BC 105. Acta Scand 1969; 45: 601-10.
220. Curran DA, Hinterberger H, Lance JW. Methysergide. Res Clin Stud Headache 1967; 1: 74-122.
221. Krabbe A. Limited efficacy of methysergide in cluster headache: a clinical experience. Cephalalgia 1989; 9: 404-5.
222. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989; 9: 195-8.
223. Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology 1999; 53: 234-6.
224. Waldenlind E, Ekbom K, Wetterberg L i sur. Lowered circannual urinary cluster headache. Cephalalgia 1994; 14: 199-204.
225. Leone M, D'Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16: 494-6.
226. Marks DR, Rapoport A, Padla D i sur. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993; 13: 114-6.
227. Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. The treatment of cluster headache with repetitive intraveneous dihydroergotamine. Headache 1991; 31: 525-32.
228. Dodick DW, Rozen TD, Goadsby PJ, Silberstein SD. Cluster headache 2000; 20: 787-803.
229. Onofrio BM, Campbell JK. Surgical treatment of chronic cluster headache. Mayo Clin Proc 1986; 61: 537-44.
230. Mathew NT, Hurt W. Percutaneous radiofrequency trigeminal gangliorhizolysis in intractable cluster headache. Headache 1988; 28: 328-31.
231. Taha JM, Tew JM. Long-term results of radiofrequency rhizotomy in the treatment of cluster headache. Headache 1995; 35: 193-6.
232. Peper DR, Dickerson J, Hassenbusch SJ. Percutaneous retrogasserian glycerol rhizolysis for treatment of chronic intractable cluster headaches: long-term results. Neurosurgery 2000; 46: 363-8.
233. Ford RG, Ford KT, Swaid S, Young P, Jenelle R. Gamma knife treatment of refractory cluster headache. Headache 1998; 38: 3-9.
234. Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29: 648-56.
235. Evers S, Goadsby PJ. Hypnic headache. Clinical features, pathophysiology and treatment. Neurology 2003; 60: 905-9.